Charles A. McWherter
2019
In 2019, Charles A. McWherter earned a total compensation of $1.5M as Chief Scientific Officer at Cymabay Therapeutics, a 16% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $84,732 |
|---|---|
| Option Awards | $994,279 |
| Salary | $423,662 |
| Other | $6,254 |
| Total | $1,508,297 |
McWherter received $994.3K in option awards, accounting for 66% of the total pay in 2019.
McWherter also received $84.7K in non-equity incentive plan, $423.7K in salary and $6.3K in other compensation.
Rankings
In 2019, Charles A. McWherter's compensation ranked 7,292nd out of 13,971 executives tracked by ExecPay. In other words, McWherter earned more than 47.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,292 out of 13,971 | 48th |
Division Manufacturing | 2,809 out of 5,701 | 51st |
Major group Chemicals And Allied Products | 1,047 out of 2,200 | 52nd |
Industry group Drugs | 891 out of 1,886 | 53rd |
Industry Pharmaceutical Preparations | 661 out of 1,398 | 53rd |
Source: SEC filing on May 15, 2020.
McWherter's colleagues
We found four more compensation records of executives who worked with Charles A. McWherter at Cymabay Therapeutics in 2019.
News
Cymabay Therapeutics CEO Sujal Shah's 2022 pay rises 16% to $2.6M
April 19, 2023
Cymabay Therapeutics CEO Sujal Shah's 2021 pay slips 16% to $2.2M
April 26, 2022
Cymabay Therapeutics CEO Sujal Shah's 2019 pay jumps 32% to $2.6M
May 15, 2020
Cymabay Therapeutics General Counsel Paul Quinlan receives $3M in 2018
April 26, 2019